Have you heard of magic mushroom stocks? Pot stocks gave investors excellent returns in 2020. However, most investors did miss out on this opportunity. For the most part, magic mushrooms are largely illegal in the US, and research has shown the drug’s effectiveness at treating conditions like depression, anxiety, and opioid addiction.
Table of Contents
- Are Magic Mushroom’s Legal in US?
- Top Psychedelic Stocks
Are Magic Mushroom’s Legal in US?
No they’re not. As a result, you’re not going to find magic mushroom stocks to trade. Don’t let that discourage you however. There are are psychedelic’s you can trade. And there have been studies that something like magic mushrooms can help with medical and mental issues. This, of course, would be done with professionals and not something you get off the street.
Latest Industry News for Magic Mushroom Stocks
As of late, this industry has been demonstrating its potential. Therefore, it might not be a bad idea to look into the investment world of psychedelics. Psychedelic stocks are in a sector that most people would classify as a fast-moving sector. Many analysts consider this sector as speculative and overpriced.
Psychedelic companies are expected to have an additional price increase in 2021. However, the real money that will be made via psychedelic companies will be via FDA-approved drugs to treat depression and mental health.
While our likelihood of seeing psychedelic products on shelves is low, microdosing and psychedelic assisted therapy are now hitting the mainstream channels.
Quite a few companies have also gained early popularity, like Mind Med, because of who is backing them. With this information in light, let’s look at some Psychedelic stocks that have the potential to go up significantly in value. So while you can’t trade magic mushroom stocks, you do have options.
Top Psychedelic Stocks
Mindmed (OTCQB: MMEDF)
MindMed (OTCQB: MMEDF) is a company that offers a highly diverse range of psychedelic drugs in clinical development and also in R&D. Digital therapeutics are evidence-based therapeutic interventions for patients that help them manage, prevent or treat a mental disorder or disease.
The company has multiple FDA-approved trials underway in numerous jurisdictions and also in various geographies. Mind medicine aims to use substances like psilocybin, LSD, and also MDMA for harsh psychiatric conditions.
Mind med is a good company because of its underway development projects, and they already have a pipeline of early-stage trials underway. However, experienced pharma investors are a little apprehensive because most of Mind Meds chemicals being developed have already been discovered.
Therefore they cannot be patented because they were of natural origin or were found long ago by someone else. However, the company will still be top-rated and secure because of all its intellectual property breakthroughs.
Mind medicine is one of the more advanced companies, but it is severely undervalued in its projects and big-name collaborators. This makes it a good investment because the future growth potential of this medicine is very bright.
Mydecine Innovations Group (OTC: MYCOF Stock Report) (CSE: MYCO)
MYCOF stock has been experiencing an upward stock price movement for the last few weeks. Part of the increase in MYCOF stock value can also be attributed to the company’s recent commercial export of legal psilocybin mushrooms to Canada. The company has also been able to complete its recent harvest in their Jamaican facility.
Mushrooms are being used for their compounds, and these compounds are being extracted and refined by Mydecine and made available for purchase by other licensed companies. Mydecine is also planning to study the compounds for potential use down the line in psilocybin-assisted psychotherapy for PTSD.
Mind Cure Health Inc. (OTC: MCURF Stock Report)
MCUR is one of the lesser discussed magic mushroom stocks; however, the stock has been experiencing a higher level of momentum as of late. The penny stock, however, is not traded as frequently as other stocks in its category.
The company has recently announced its psychedelic research program, and the initial focus will be on psilocybin, ketamine, and ibogaine. The company aims to provide its patients with treatments with ketamine and psilocybin.
20/20 Global (OTC Pink: TWGL)
The company is a relatively new company to the psychedelic world, and it is a fully reporting issuer to the securities and exchange commission. Ehave is another psychedelic company in digital therapeutics and is developing a ketamine delivery platform that goes by the name of KetaDASH.
They’ve sold 100% of its Mycotia therapies subsidiary to 20/20 Global while simultaneously acquiring 75% of Globals outstanding shares. 20/20 Global will be looking into other business opportunities, which include psychedelic retreats and also medicinal mushrooms.
Havn Life Sciences and Magic Mushroom Stocks
Havn life sciences have managed to gain a lot of investor attention and also much popularity because of the big names it owns. If you talk about the popular names in cannabis, Aphira is likely to be in the top five. The CEO of Aphira Havn. Vic Neufeld is behind Havn life sciences.
Havn life sciences have also announced a new partnership with veterans mental health non-profit, Westwood Institute. This partnership is strategic in nature and aims to work on developing therapy using psychedelics for veterans.
Havn has also recently gone ahead and signed an MOU helping supply products and compounds for use in Heroic Heart’s future clinical studies. The company aims to research and investigate the effect of low dosage psychedelic compounds on veterans suffering from emotional trauma and PTSD.
Numinous wellness is a company that the Canadian government has recently licensed to cultivate, extract, and sell naturally sourced, sustainable psilocybin, also known as magic mushrooms. They’re also the owner of a dealer’s license.
Which means that the company can import, export, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline. Numinus offers three pathways for psychedelic-assisted psychotherapy.
The company has also been trading high six-figure and low seven-figure dollar volume daily. Numinus wellness has a great business plan and has a couple of credible advisors onboard.
However, it does not file audited financials on the US Securities and Exchange Commission’s EDGAR system.
The magic mushroom stocks industry could be on the brink of a boom, and it might make sense to invest some portion of your shares into these magic mushroom tocks. The growth charts are positive and even if there isn’t a massive price increase like we predict. There’ll be a substantial price increase which can help investors turn out a good profit.
The competition between the dozens of biopharmaceutical companies is fierce. Many companies are seeking capital through which they can conduct expensive and lengthy drug trials and develop intellectual property and help advance the treatment for various mental disorders. Whether you’re day trading or investing, these are options for you.